Loading...
FDA Approval And Cell Therapies Will Transform DMD Patient Care
AN
AnalystHighTarget
Not Invested
Consensus Narrative from 10 Analysts
Published
26 Aug 25
Updated
26 Aug 25
AnalystHighTarget's Fair Value
US$29.00
78.3% undervalued intrinsic discount26 Aug
US$6.28
1Y
37.4%7D
-4.8%1Y
37.4%7D
-4.8%